FDA 483 - Kohana Pharmacy and Center for Regenerative Medicine Inc. - April 10, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Kohana Pharmacy and Center for Regenerative Medicine Inc. in San Luis Obispo, CA, identified significant deficiencies in the production of non-sterile drug products. The firm was cited for using non-pharmaceutical grade components, specifically purified water, in drug formulations. Additionally, the inspection revealed inadequate cleaning procedures for work surfaces and utensils used in the production of hazardous drugs, posing a risk of cross-contamination.
- Inspection Date
- April 10, 2019
- Product Type
- Drugs
ID · 53aa7ab8-817d-43e0-8196-65678cd3f013